| Literature DB >> 31131660 |
Margaret M Fuchs1, Christine Attenhofer Jost1, Dusica Babovic-Vuksanovic2, Heidi M Connolly1, Alexander Egbe1.
Abstract
Background Turner syndrome ( TS ) is the most common sex chromosome abnormality in women and is associated with increased morbidity and mortality. We describe long-term outcomes in a large cohort of patients with TS . Methods and Results Retrospective review of patients with TS followed at Mayo Clinic Rochester from 1950 to 2017 was performed. Clinical, imaging, surgical, and genetic data were analyzed. Survival analysis was performed with the Kaplan-Meier method using age- and sex-matched Olmsted County residents as the reference group. The study cohort comprised 317 patients with TS . Average age at diagnosis was 9 (range, 2-12) years, genetic testing was performed in 202 (64%), and pure monosomy X was present in 75 (37%). Congenital heart disease occurred in 131 (41%), with the most frequent lesions being bicuspid aortic valve (n=102, 32%) and coarctation of the aorta (n=43, 14%). Ascending aortic dilation was common, with mean aortic root size index 2 cm/m2, and aortic dissection occurred in 6 (2%) patients. The average follow-up was 11 (range, 2-26) years, yielding 3898 patient-years, and during this period 46 (14%) patients died; mean age at the time of death was 53±17 years. Patients with TS had reduced survival compared with the control group (82% versus 94% at 30 years; P<0.001), and the leading causes of death were cardiovascular disease, liver disease, and malignancy. Conclusions Patients with TS have reduced survival compared with age-matched controls, and cardiovascular disease is the major cause of death. Further studies are required to determine if targeted cardiovascular risk factor modification will result in improved survival in this population.Entities:
Keywords: Turner syndrome; aortic disease; congenital heart disease
Mesh:
Year: 2019 PMID: 31131660 PMCID: PMC6585378 DOI: 10.1161/JAHA.118.011501
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Baseline Characteristics (N=317)
| Age at the beginning of study, y | 22±18 |
| Height, cm | 143±16 |
| Weight, kg | 57±11 |
| Body surface area, m2 | 1.49±0.41 |
| Body mass index, kg/m2 | 26±8 |
| Comorbidities | |
| Hypertension | 98 (31%) |
| Hyperlipidemia | 79 (25%) |
| Coronary artery disease | 19 (6%) |
| Current or prior smoker | 26 (8%) |
| Diabetes mellitus | 37 (12%) |
| Sleep apnea | 27 (9%) |
| Prior stroke | 11 (4%) |
| Hypothyroidism | 104 (33%) |
| Congenital heart disease | |
| Bicuspid aortic valve | 102 (32%) |
| Coarctation of aorta | 43 (14%) |
| Persistent left superior vena cava | 24 (8%) |
| Anomalous pulmonary vein | 18 (6%) |
| Others | 22 (7%) |
| Medications | |
| Diuretics | 36 (11%) |
| Beta and/or calcium channel blockers | 54 (17%) |
| RAAS antagonist | 48 (15%) |
| Warfarin | 15 (5%) |
| Direct oral anticoagulants | 1 (3%) |
| Aspirin | 39 (12%) |
| Statin | 37 (12%) |
| Levothyroxine | 72 (23%) |
| Estrogen | 181 (57%) |
| Growth hormone | 88 (28%) |
RAAS indicates renin‐angiotensin‐aldosterone system.
Echocardiography
| Left ventricle | |
| Left ventricular ejection fraction, % | 62±7 |
| Left ventricular end‐diastolic dimension, mm | 43±7 |
| Left ventricular end‐systolic dimension, mm | 29±4 |
| Left ventricular mass index, g/m2 | 78±24 |
| Aortic valve annulus | |
| Aortic valve annulus, mm | 19±3 |
| Aortic valve annulus, | 0.4 (−0.3 to 1.1) |
| Aortic root/sinus of Valsalva | |
| Aortic root/sinus of Valsalva, mm | 28±6 |
| Aortic root/sinus of Valsalva, | 0.8 (−0.2 to −1.6) |
| Aortic root/sinus of Valsalva, | 44 (14%) |
| Aortic size index, cm/m2 | 2.0±0.6 |
| Aortic size index, ≥2.5 cm/m2 | 38 (12%) |
| Mid–ascending aorta | |
| Mid–ascending aorta, mm | 28±8 |
| Mid–ascending aorta, | 1.1 (−0.1 to 2.0) |
| Mid–ascending aorta, | 59 (19%) |
| Aortic size index, cm/m2 | 1.9±0.6 |
| Aortic size index, ≥2.5 cm/m2 | 37 (12%) |
Figure 1Kaplan–Meier curve comparing survival between the patients with Turner syndrome (blue) vs Olmsted County residents (red).
Figure 2Kaplan–Meier curve comparing survival between. A, Patient with congenital heart disease (CHD) (blue) vs patients without CHD (red); 30‐year survival was 79% in CHD patients vs 83% in patients without CHD. B, Patients with genetic testing (red) vs patients without genetic testing (blue); 30‐year survival was 84% in patients who had genetic testing vs 77% in patients without genetic testing. C, Patients with bicuspid aortic valve (red) vs patients without bicuspid aortic valve (blue); 30‐year survival was 83% in patients with bicuspid aortic valve vs 82% in patients without bicuspid aortic valve.